Canadian trials to examine "liberation procedure" for multiple sclerosis

June 2010
CMAJ: Canadian Medical Association Journal;6/15/2010, Vol. 182 Issue 9, pE403
Academic Journal
The article presents a reprint of the article "Canadian trials to examine liberation procedure for multiple sclerosis," by Becky Rynor, which appeared at www.cmaj.ca in the May 3, 2010. It discusses the clinical investigations being considered regarding a surgery for multiple sclerosis, called the liberation procedure. It states that the operation is not yet tested clinically, that is why some Canadian researchers undertake research project to validate the the findings on liberation procedure.


Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;4/19/2010, Vol. 21 Issue 74, p8 

    This section discusses two clinical studies including the use of EMD Serono's Cladribine tablets for multiple sclerosis (MS), and the Phase II study of the KNS-760704 drug from Knopp Neurosciences Inc., in amyotrophic lateral sclerosis.

  • What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? Asano, M.; Dawes, D. J.; Arafah, A.; Moriello, C.; Mayo, N. E. // Multiple Sclerosis (13524585);Apr2009, Vol. 15 Issue 4, p412 

    Objective The goal of this review is to ascertain the extent to which the current body of research on the role of exercise in multiple sclerosis (MS) provides sufficiently strong evidence to guide regular exercise prescription. Methods We searched CINAHL, COCHRANE, EMBASE, and MEDLINE between...

  • Glatiramer effective in delaying clinical MS.  // Formulary;Jun2008, Vol. 43 Issue 6, p220 

    The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying...

  • Glatiramer, interferon beta-1b comparable in early RRMS.  // Formulary;Jun2008, Vol. 43 Issue 6, p222 

    The article reports on the findings of the study regarding the efficacy of interferon beta-1b with glatiramer for reducing relapse risk in patients with early relapsing-remitting multiple sclerosis (RRMS). Study author Paul O'Connor of St. Michael's Hospital in Toronto, Ontario found that the...

  • Acorda reports positive interim data Phase III multiple sclerosis trial.  // PharmaWatch: CNS;Oct2009, Vol. 8 Issue 10, p5 

    The article discusses the report of Acorda Therapeutics Inc. regarding a long-term open label extension study which examines the effectiveness of Fampridine-SR in improving the walking speed of multiple sclerosis patients. It notes that walking speed among MS patient treated with Fampridine-SR...

  • Genzyme and Bayer: alemtuzumab - miracle cure or another Tysabri?  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p4 

    The article reports on the result of Genzyme Corp. and Bayer AG's Phase II clinical trial study on alemtuzumab for the treatment of multiple sclerosis (MS). It relates that results from the final three-year analysis of the 334-patient, the drug was found to reduce the risk of relapse by 74% and...

  • Opexa reports additional positive data from Phase IIb multiple sclerosis study.  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p9 

    The article reports on additional positive results from Opexa Therapeutics Inc.'s Phase IIb clinical trial for Tovaxin for the treatment of multiple sclerosis. The findings indicate that Tovaxin demonstrated a benefit across all clinical and magnetic resonance imaging endpoints in prospective...

  • Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Turner, A. P.; Kivlahan, D. R.; Sloan, A. P.; Haselkorn, J. K. // Multiple Sclerosis (13524585);Nov2007, Vol. 13 Issue 9, p1146 

    Objective To evaluate ongoing adherence to disease modifying therapies (DMT) among individuals with multiple sclerosis and test the utility of the Health Beliefs Model (HBM) to predict adherence. Design Telephone survey completed at baseline with monthly telephone follow-up for 6 months. Setting...

  • Galapagos initiates Phase II multiple sclerosis trial.  // PharmaWatch: CNS;Jan2010, Vol. 9 Issue 1, p4 

    The article reports that the biotechnology company Galapagos NV has started a Phase II clinical study for evaluating the effectiveness of the drug Nanocort in treating flares in multiple sclerosis or MS. The trial will involve 90 MS patients experiencing flares, episodes of increased...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics